Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Eur J Haematol. 2024 Jan;112(1):36-40. doi: 10.1111/ejh.14071. Epub 2023 Aug 1.
Collections of lymphocytes to be genetically modified to treat hematologic malignancies have seen a dramatic increase over the last few years as commercial products have been approved. Reports of new products in development that can possibly treat solid organ malignancies represent a massive change in the field. Apheresis is at the center of the collection of cells for the manufacture of these chimeric-antigen receptor therapy products. The expansion of these collections represents one of the areas of apheresis procedures growth. This review will summarize concepts important to this type of collection and variables that need to be optimized to obtain desired cell yields while increasing patients' safety.
近年来，随着商业产品的批准，用于治疗血液系统恶性肿瘤的淋巴细胞遗传修饰物的采集数量急剧增加。新的治疗实体器官恶性肿瘤的产品的开发报告代表了该领域的重大变化。细胞采集是这些嵌合抗原受体治疗产品制造的核心。这些采集的扩展代表了血浆分离术程序增长的一个领域。本文综述了这一类型采集的重要概念，以及需要优化的变量，以在提高患者安全性的同时获得所需的细胞产量。
